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Georgia Southern University
Jiann-Ping Hsu College of Public Health
BIOS 7231 – Clinical Trial Methodology
Spring 2015

Instructor:
Office:
Phone:
E-Mail Address:
Office Hours:
Web Page:
Class Meets:

Karl E. Peace
Hendrix Hall #1005
912-478-7905
kepeace@georgiasouthern.edu or peacekarl@frontier.com
Wednesday – 3:00 PM – 5:00 PM
And – By appointment, any time via email
http://www.georgiasouthern.edu/~kepeace/
Wednesday – 5:00 PM-to-7:30 PM via electronic classroom 2 weeks of each
Month and onsite 2 weeks of each month.

-- Course schedules can be found at: http://www.collegesource.org/displayinfo/catalink.asp --

Prerequisites:

BIOS 6541; BIOS 7534

VISTA Address:

Via MyGeorgiaSouthern on GSU Home Page

Catalog Description:

Students are introduced to regulatory, scientific, statistical and
practical aspects of methods inherent in design, monitoring and
analysis of clinical trials. Clinical trials in many areas of drug
development are presented, discussed and critiqued.

Required Textbook:

Clinical Trial Methodology by Karl E. Peace and Din Chen
Series: Chapman & Hall/CRC Biostatistics Series
Cat. #: C9179
ISBN: 9781584889175
ISBN 10: 1584889179
Publication Date: July 19, 2010
Number of Pages: 420
The course is presented using power points. Students are
provided copies of the power points on a Flash Drive.
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Secondary Texts:
Chen D, Peace KE (2010): Clinical Trial Data Analysis using R; Chapman & Hall/CRC, Taylor
and Francis Group; ISBN: 978-1-4398-4020-7
Chen, D, Peace KE: Applied Meta-Analysis using R. Chapman & Hall/CRC, Taylor and Francis
Group; 13: 978-1-4665-0599-5; May, 2013.
Chen D, Sun J, Peace KE [Editors and Author contributors] (2012): Interval-Censored Time-toEvent Data: Methods and Applications"; Chapman & Hall/CRC,
Taylor and Francis Group; Published July, 2012.
Peace, K. E. [Editor and Author contributor] (2008): Design and Analysis of Clinical Trials with
Time to Event Endpoints; Chapman & Hall/CRC Taylor and Francis
Group; Boca, ISBN 978-1-4200-6639-5.
Peace, K. E. [Editor and Author contributor] (1992): Biopharmaceutical Sequential Statistical
Applications. Marcel Dekker, Inc., New York, ISBN 0-8247-8628-9.
Peace, K. E. [Editor and Author contributor] (1990): Statistical Issues in Pharmaceutical Drug
Development. Marcel Dekker, Inc., New York, ISBN 0-8247-8290-9.
Peace, K.E. [Editor and author] (1988): Biopharmaceutical Statistics in Drug Development.
Marcel Dekker, Inc., New York, ISBN 0-8247-7798-0.
M.P.H. Biostatistics Concentration Competencies:
Upon graduation a student with an M.P.H. in Biostatistics should be able to:
1. Construct a public health and biomedical research question from ideas, conditions, and
events that exist in a rural and urban community, region, state, and nation using critical
thinking skills;
2. Identify objectives of a public health and biomedical research question;
3. Express objectives in the appropriate biostatistical framework such as hypothesis testing,
estimation, and prediction;
4. Evaluate objectives of a public health research question to ensure the appropriate type of
data is collected for analysis;
5. Design an experiment or survey pertaining to a public health and biomedical research
question in order to collect the data needed to meet objectives of public health research;
6. Apply appropriate statistical tools and software in order to analyze data;
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7. Demonstrate use of Statistical Analysis Software (SAS) to input, manage, merge, export,
and conduct analysis on public health and biomedical data;
8. Analyze data using appropriate categorical analysis techniques to obtain valid and
reliable results;
9. Analyze quantitative data using appropriate biostatistical methods such as simple and
multiple regression and clinical trial methodology;
10. Provide statistical requisites for developing a protocol for conducting a clinical trial;
11. Describe key concepts and theory underlying biostatistical methodology used in
probability and inferential, analytical, and descriptive statistics;
12. Interpret results of biostatistical analyses so that valid and reliable conclusions regarding
a public health and biomedical research question may be drawn from the analyses;
13. Develop written and oral reports to communicate effectively to research investigators
pivotal aspects of a study, including its design, objectives, data, analysis methods, results,
and conclusions;
14. Create a collaborative environment for working on written and oral reports and
developing critical thinking skills.

Course Objectives: At the end of this course, students will be able to:
1. Translate public health and biomedical research objectives into statistical hypotheses
(competencies 1, 2, 3, 4)
2. Design public health and biomedical research clinical trials (competencies 1, 2, 3, 4,

5)
3. Develop Statistical Analysis Sections for pubic health and biomedical research

Protocols (competencies 1, 2, 3, 4, 5, 8, 9, 10)
4. Explain the requirements for good protocol development for public health and

biomedical research clinical trials (competencies 1, 2, 3, 4, 5, 8, 9, 10, 13, 14)
5. Apply common statistical descriptive and inferential analysis methods to data

collected in public health and biomedical research clinical trials (competencies 6, 7,
8, 9)
6. Describe methodological alternatives to commonly used statistical methods used in

public health and biomedical research clinical trials when analysis assumptions are
not met (competencies 6, 7, 8, 9)

3

7. Interpret results of statistical analyses of data collected from public health and

biomedical clinical trials (competency 12)
8. Develop written and oral presentations based on statistical analyses of public health

and biomedical research clinical trials, for both public health professionals and
educated lay audiences (competencies 12, 13, 14)
9. Identify key federal regulation ‘governing’ the conduct of clinical trials (competency

10)
10. Explain the importance of the numbers of patients in clinical trials (competency 11)
11. Explain the importance of monitoring adverse experiences in clinical trials

(competencies 2, 5, 6 ,10)
12. Describe methods for monitoring adverse experiences in clinical trials (competencies
2, 5, 6, 10)
13. Explain how data from multicentre clinical trials may be ‘pooled’ (competencies 6, 7,
8, 9, 10, 13)
14. Describe the issues in group sequential clinical trials (competencies 11, 12, 13)

Instructional Methods: Class meetings will be a combination of lecture and class discussion.
Approximately half of the class meetings will be facilitated via Adobe Connect in real time
(blended format) and the remainder physically in the classroom. Homework assignments, class
participation and the final examination constitute the basis of student evaluation. Students are
expected to make use of office hours and email contact to discuss concepts or difficulties they
may have. In addition, they may seek the assistance of the GA.
Daily Study Log: Students are required to keep a daily computerized study log. The study log
should have a column for the date, a column to identify topic of study, a column to identify the
time of beginning study, a column to identify the ending time of study, and a column to identify
the amount of time spent in studying the topic.
Final Examination: May ??
May ??

Last day of classes
Final exams

Grading: Weighting of assignments for purposes of grading will be as follows:
Final Exam (objectives 1-14, integrated)……………60%
Assignment (objectives 1-14, individually)……. …..30%
Class Participation (objectives 1-14, individually)…10%
____
Total Possible
100%
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The following point scale will be utilized in grading:
90% - 100%

A

80% - 90%

B

70% - 80%

C

60% - 70%

D

There are times when extraordinary circumstances occur (e.g., serious
illness, death in the family, etc.). In such circumstances, and/or if you
need additional time to satisfactorily complete any course requirement,
please consult with the instructor within a reasonable amount of time.
Academic Misconduct: As a student registered at this University, it is expected that you will
adhere to only the strictest standards of conduct. It is recommended
that you review the latest edition of the Student Conduct Code book, as
well as the latest Undergraduate & Graduate Catalog to familiarize
yourself with the University’s policies in this regard. Your continued
enrollment in this course is an implied contract between you and the
instructor on this issue; from this point forward, it is assumed that you
will conduct yourself appropriately.
Academic integrity relates to the appropriate use of intellectual
property. The syllabus, lecture notes, and all materials presented
and/or distributed during this course are protected by copyright law.
Students are authorized to take notes in class, but that authorization
extends only to making one set of notes for personal (and no other)
use. As such, students are not authorized to sell, license, commercially
publish, distribute, transmit, display, or record notes in or from class
without the express written permission of the instructor.
Academic Handbook:

Students are expected to abide by the Academic Handbook, located at
Your failure to comply
with any part of this Handbook may be a violation and thus, you may
receive an F in the course and/or be referred for disciplinary action.
http://students.georgiasouthern.edu/sta/guide/.

University Calendar
for the Semester:

Attendance Policy:

The University Calendar is located with the semester schedule, and
can be found at:
http://students.georgiasouthern.edu/registrar/calendar.htm

Federal regulations require attendance be verified prior to distribution
of financial aid allotments. Attendance will not be recorded after this
initial period.
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One Final Note:

The contents of this syllabus are as complete and accurate as possible.
The instructor reserves the right to make any changes necessary to the
syllabus and course material. The instructor will make every effort to
inform students of changes as they occur. It is the responsibility of the
student to know what changes have been made in order to successfully
complete the requirements of the course.

Overview of the Content to be Covered During the Semester:
Module I: An Overview of the Regulation of Pharmaceuticals
Module II: An Overview of the Processes of Discovery, Basic Research, Clinical Development
and Manufacturing in Pharmaceutical Development
Module III: Biostatistical Aspects of Clinical Drug Development
A. The Components of a Protocol
B. Statistical Analysis Section of a Clinical Trial Protocol
Module IV: Bioavailability & Bioequivalence of Pharmaceutical Formulations
Module V: The Design and Analysis of Pivotal Clinical Trials to Assess the Efficacy of Drugs to
Treat Panic Disorder
Module VI: Clinical Trials in the Prevention of NSAID Induced Gastric Ulceration
Module VII: Biostatistical Aspects of the Development of H2-Receptor Antagonist Drugs in the
Treatment of Duodenal Ulcers
Module VIII: Biostatistical Aspects of the Development of Antianginal Drugs
Module IX: Biostatistical Aspects of the Development of Drugs to Treat Alzheimer’s disease
Based upon Enrichment Designs
Module X: The Importance of Numbers (of Patients) in Cancer Clinical Trials
Module XI: Biostatistical Aspects of the Design of Cancer Trials
Module XII: Biostatistical Aspects of the Analysis and Interpretation of Cancer Clinical Trials
Module XIII: Monitoring Adverse Experiences in Clinical Drug Development
Module XIV: The Pooling of Data from Multicenter Clinical Trials
Module XV: Interim Analyses: p-Value and Power Computations in Multiple Look Trials
Module XVI: Statistical Analysis of Dose Response Trials

6

Student Information (CTM Class):
Print Full Name

email address

Pledge to spend enough time
to master material? Circle one.

1. ________________

________________

Yes

No

Undecided

2. ________________

________________

Yes

No

Undecided

3. ________________

________________

Yes

No

Undecided

4. ________________

________________

Yes

No

Undecided

5. ________________

________________

Yes

No

Undecided

6. ________________

________________

Yes

No

Undecided

7. ________________

________________

Yes

No

Undecided

8. ________________

________________

Yes

No

Undecided

9. ________________

________________

Yes

No

Undecided

10. ________________

________________

Yes

No

Undecided

11. ________________

________________

Yes

No

Undecided

12. ________________

________________

Yes

No

Undecided
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